Background Obesity is a major contributor to cardiovascular disease (CVD). Different fat depots may have distinct effects on ...
Background Effective decongestion is a key therapeutic goal during hospitalisation for acute heart failure (HF), but the ...
For more than two decades, the crucial dilemma of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has remained unchanged: the same therapies used to treat myocardial ...
Background Fluid restriction is a commonly prescribed non-pharmacological intervention in the management of heart failure (HF). However, data on its efficacy and safety are scarce. Recent randomised ...
Background The impact of COVID-19 in hypertrophic cardiomyopathy (HCM), particularly in the post-vaccine era, remains ...
Background Pericarditis may be associated with significant morbidity and mortality and can be a clinically challenging entity ...
Pericarditis remains a clinical diagnosis. No single symptom, biomarker, electrocardiographic pattern or imaging finding is sufficiently sensitive and specific across the full spectrum of disease. The ...
In the early 2000s, the natural history of heart failure (HF) was vividly illustrated, highlighting a defining feature of HF progression: a prolonged course of fluctuating yet steadily worsening ...
Background Hypochloraemia has emerged as a prognostic marker in heart failure, although the mechanisms underlying chloride ...
Correspondence to Dr Sakineh Shab-Bidar, Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran 14155/6117, Iran; s_shabbidar{at ...
Correspondence to Dr Sarah Zaman, Westmead Applied Research Centre, The University of Sydney, Sydney, New South Wales, Australia; sarah.zaman{at}sydney.edu.au Background Conflicting evidence surrounds ...
Correspondence to Dr Milind Y Desai, Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Foundation, 9500 Euclid Ave, Desk J1.5, Cleveland, OH 44195, USA; ...